<html xml:lang="en-us" lang="en-us" xmlns="http://www.w3.org/1999/xhtml" xmlns:epub="http://www.idpf.org/2007/ops"><head>
    <link rel="stylesheet" type="text/css" href="../../css/base.css" />
<link rel="stylesheet" type="text/css" href="../../css/kotobeeInteractive.css" />
<link rel="stylesheet" type="text/css" href="../../css/global.css" />

    <script type="text/javascript" src="../../js/kotobeeInteractive.js"></script>
<script type="text/javascript" src="../../js/global.js"></script>

    <title>Venous Thrombo-Embolism Prophylaxis</title>
    

<meta name="m-checksum" content="672780469" />
<meta charset="utf-8" />
 <meta name="kotobee-chapter" content="raw\ske760.xhtml" />
<meta name="kotobee-book" content="urn:uuid:7220855b-f459-176d-2516-3512d7acb694" />
</head>
<body>
<p>The decision to give DVT pharmacological prophylaxis in a palliative care patient requires carefully weighing up the benefits and risks. It is often inappropriate in patients who are in their last few weeks of life and tends to be mostly reserved for palliative patients who have an acute illness or acutely worsened mobility that is expected to be short-term and improve. The following chart summarizes the well-known Pan-Birmingham Guidelines:</p>

<p>&#160;</p>

<p><img class="kInteractive image image874" data-kotobee="Tlg2SlBXDEhCREdGUgEHBwNYSlBXB0BNAAMdBx1XWV1OSlBXC0pLBFBGWkNXWV0SAw0EEQAXU09RWl0cBAERSlBXSQAXUxgVGggbBUpGXVhQSQAXUwUbGBoCTl1GVRYXEEAJREdGGAACHh8nBhgAQBcXW1BGWgIXDwYBAkdXVwkAU0cQARwTCQMROBAEFWNKEzgbCgYeDkpGXVgRF1BATVBGWgweChwHAQMIAAAXU09RWl0bBg4TClpSUQAXU1lRWl0WAgJRXVBfC1BJDVlRWl0XEwYHGxEsC2hABRwVJAYQGQ4GFkdXVx9DABkHDUNXWV0HGxsJAAAXU08aHQMeR0pGXQsIAnpDCBkRBg4fDkpGXVgLEElJTVBGWh8THwdRXVBfQBcXT1tbRkFdAgITHE0TEUALMTszTV1ATlgw" src="../../imgs/vte.PNG" style="margin: 5px auto; position: static;" /><br />
&#160;</p>




</body></html>